FANTINI, MASSIMO CLAUDIO
 Distribuzione geografica
Continente #
EU - Europa 66.693
NA - Nord America 7.130
AS - Asia 3.727
SA - Sud America 916
Continente sconosciuto - Info sul continente non disponibili 442
AF - Africa 98
OC - Oceania 24
Totale 79.030
Nazione #
IT - Italia 65.442
US - Stati Uniti d'America 6.982
SG - Singapore 1.589
CN - Cina 1.005
BR - Brasile 716
VN - Vietnam 441
SE - Svezia 349
FI - Finlandia 260
HK - Hong Kong 174
FR - Francia 159
DE - Germania 146
GB - Regno Unito 122
IN - India 99
BD - Bangladesh 78
AR - Argentina 69
CA - Canada 62
MX - Messico 45
NL - Olanda 43
EC - Ecuador 41
IQ - Iraq 40
KR - Corea 34
TR - Turchia 34
CO - Colombia 32
PK - Pakistan 29
ZA - Sudafrica 29
ID - Indonesia 27
AT - Austria 26
JP - Giappone 25
UZ - Uzbekistan 25
AU - Australia 22
PL - Polonia 21
EG - Egitto 17
MA - Marocco 17
ES - Italia 16
PY - Paraguay 16
SA - Arabia Saudita 15
UA - Ucraina 15
PH - Filippine 14
CZ - Repubblica Ceca 12
JM - Giamaica 12
VE - Venezuela 12
KZ - Kazakistan 11
MY - Malesia 11
RU - Federazione Russa 11
IL - Israele 9
JO - Giordania 9
PE - Perù 9
AZ - Azerbaigian 8
CH - Svizzera 8
CL - Cile 8
IE - Irlanda 8
LB - Libano 8
NP - Nepal 8
HU - Ungheria 7
KE - Kenya 7
OM - Oman 7
TN - Tunisia 7
DK - Danimarca 6
DO - Repubblica Dominicana 6
BG - Bulgaria 5
GR - Grecia 5
GT - Guatemala 5
KG - Kirghizistan 5
UY - Uruguay 5
DZ - Algeria 4
ET - Etiopia 4
LT - Lituania 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
BO - Bolivia 3
GY - Guiana 3
HN - Honduras 3
IR - Iran 3
MD - Moldavia 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
BH - Bahrain 2
CR - Costa Rica 2
FJ - Figi 2
IS - Islanda 2
KW - Kuwait 2
LU - Lussemburgo 2
LV - Lettonia 2
NI - Nicaragua 2
QA - Qatar 2
SN - Senegal 2
UG - Uganda 2
AM - Armenia 1
AO - Angola 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
Totale 78.570
Città #
Cagliari 61.521
Uta 3.531
Fairfield 883
Singapore 779
Ashburn 698
San Jose 406
Woodbridge 403
Seattle 383
Dallas 358
Boardman 332
Houston 329
Cambridge 318
Wilmington 298
Nyköping 253
Council Bluffs 228
Helsinki 228
Los Angeles 169
Beijing 152
Santa Clara 152
Ho Chi Minh City 140
Hong Kong 138
Ann Arbor 108
New York 107
Lauterbourg 105
Boston 99
Hanoi 85
Jacksonville 81
Hefei 69
Shanghai 68
Buffalo 60
São Paulo 58
Rome 54
Milan 47
Chandler 46
San Diego 46
Columbus 42
The Dalles 38
Dearborn 37
Hangzhou 36
Munich 36
Dong Ket 32
Orem 32
Redwood City 31
Frankfurt am Main 30
Rio de Janeiro 30
Atlanta 28
Chicago 28
London 28
Seoul 28
Montreal 27
Guangzhou 26
Tashkent 21
Amsterdam 20
Nuremberg 20
Tokyo 20
Da Nang 19
San Francisco 18
Baghdad 17
Brooklyn 17
Denver 17
Lappeenranta 17
Melbourne 17
Mountain View 17
Nanjing 17
Haiphong 16
Phoenix 16
Belo Horizonte 15
Chennai 15
Curitiba 15
Guayaquil 15
Mexico City 15
Tianjin 15
Vienna 15
Brasília 14
Johannesburg 14
Turku 14
Warsaw 14
Düsseldorf 13
Redondo Beach 13
Salt Lake City 13
Toronto 13
Ankara 12
Philadelphia 12
Biên Hòa 11
Medellín 11
Poplar 11
Quito 11
Stockholm 11
Turin 11
Zhengzhou 11
Brno 10
Norwalk 10
Wuhan 10
Asunción 9
Guarulhos 9
Jeddah 9
Las Vegas 9
Buenos Aires 8
Cairo 8
Campinas 8
Totale 73.914
Nome #
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.146
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.131
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history 1.944
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.648
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.592
RORGT-expressing tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells 1.582
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.554
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.342
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.337
Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study 1.312
Multidimensional Impact of Mediterranean Diet on IBD Patients 1.281
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 1.270
Quercetin and its derivates as antiviral potentials: A comprehensive review 1.229
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 1.215
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.189
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases 1.132
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.080
Reciprocal regulation between Smad7 and Sirt1 in the gut 1.076
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide 1.059
The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation 1.037
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 1.027
Heligmosomoides polygyrus bakeri infection decreases Smad7 expression in intestinal CD4+ T cells, which allows TGF-b to induce IL-10–producing regulatory T cells that block colitis 1.005
Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence 1.000
Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down? 996
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 961
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 957
Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death 938
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth 889
A functional role for Smad7 in sustaining colon cancer cell growth and survival 887
Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation 886
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 873
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 849
Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis 758
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages 754
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 734
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 719
Immune system and gut microbiota senescence in elderly IBD patients 711
Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis 706
Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells 694
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression 671
Smad7 expression in T cells prevents colitis-associated cancer 651
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study 634
The impact of translational research on gastroenterology 634
Reprogramming the immune system in IBD 632
null 617
Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy 598
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies 587
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations 573
Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression 572
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer 561
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine 556
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study 550
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies 546
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 532
Intestinal inflammation and colorectal cancer: a double-edged sword? 529
Inhibitory Effect of Quercetin on Oxidative Endogen Enzymes: A Focus on Putative Binding Modes 508
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 508
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6 503
Diagnostic delay in adult coeliac disease: An Italian multicentre study 502
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases 501
Regulation of homeostasis and inflammation in the intestine 497
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via a p38 Map kinase-dependent induction of SOCS-3 497
High resolution colonoscopy in live mice 489
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus 487
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut 479
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase 478
Drug insight: novel small molecules and drugs for immunosuppression 477
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid 471
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 470
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis 465
IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes 461
New players in the cytokine orchestra of inflammatory bowel disease 461
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation 454
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis 447
Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis 444
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells 439
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa 432
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy 432
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 431
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling 427
IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 423
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 417
Regulation of gut inflammation and th17 cell response by interleukin-21 416
IL-21 comes of age as a regulator of effector T cells in the gut 416
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 413
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease 413
Cytokines: from gut inflammation to colorectal cancer 406
Role of interleukin-21 in inflammation and allergy 404
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study 402
In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells 399
TGF-beta as a T cell regulator in colitis and colon cancer 398
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes 398
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease 396
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 396
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells 392
Telemedicine and remote screening for COVID-19 in inflammatory bowel disease patients: results from the SoCOVID-19 survey 384
Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy 383
Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum 383
IL-6 signaling promotes tumor growth in colorectal cancer 374
EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation 366
Totale 73.682
Categoria #
all - tutte 127.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.090


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.337 0 462 288 255 479 473 250 494 442 691 871 632
2022/20239.989 797 1.203 1.202 524 662 1.418 640 939 577 649 811 567
2023/202412.823 522 435 373 894 1.421 2.156 2.253 819 617 811 1.347 1.175
2024/202525.121 5.286 6.813 3.029 3.188 1.712 1.709 2.055 105 394 334 230 266
2025/20269.397 455 283 988 1.174 579 652 2.559 483 628 826 543 227
2026/2027620 218 402 0 0 0 0 0 0 0 0 0 0
Totale 79.030